Diabetes and pre-diabetes in USA accounted for $218 billion in costs in 2007, study shows

14 January 2010

A new analysis found that the cost of diabetes and pre-diabetes in the USA reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes Program (NCDP), a program of Denmark-based insulin giant Novo Nordisk, commissioned the analysis, which was funded by the company and is published on-line as a Web First article in Health Affairs. The work was carried out by researchers at The Lewin Group.

According to the study, diagnosed type 2 diabetes accounted for $174.4 billion of 2007 spending on diabetes and undiagnosed type 2 diabetes was responsible for $18 billion in costs. Spending on type 1 diabetes totaled $14.9 billion in 2007. Pre-diabetes, a state of elevated blood glucose that affects one in every four adults in the USA and is a precursor to diabetes, cost $25 billion. Gestational diabetes, which develops during pregnancy, was associated with $636 million in costs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical